Brian A. Mendelsohn
-
- Monoclonal and Polyclonal Antibodies Research 29
- Oncology top 2%
- HER2/EGFR in Cancer Research 28
- CAR-T cell therapy research 3
- Peptidase Inhibition and Analysis 3
- Organic Chemistry top 5%
- Click Chemistry and Applications 5
- Immunology and Allergy top 5%
- Cell Adhesion Molecules Research 5
- Molecular Biology top 10%
- Chemical Synthesis and Analysis 7
- Advanced Biosensing Techniques and Applications 3
Brian A. Mendelsohn
39 papers receiving 2.5k citations
Hit Papers
Peers
Comparison fields: 5 of 88
- Radiology, Nuclear Medicine and Imaging 1.5k
- Oncology 1.5k
- Organic Chemistry 667
- Immunology and Allergy 113
- Molecular Biology 1.0k
Countries citing papers authored by Brian A. Mendelsohn
This map shows the geographic impact of Brian A. Mendelsohn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brian A. Mendelsohn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brian A. Mendelsohn more than expected).
Fields of papers citing papers by Brian A. Mendelsohn
This network shows the impact of papers produced by Brian A. Mendelsohn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brian A. Mendelsohn. The network helps show where Brian A. Mendelsohn may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Brian A. Mendelsohn, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 2 | |
| 2 | 2025 | 1 | |
| 3 | 2024 | 1 | |
| 4 | 2023 | 42 | |
| 5 | 2021 | 25 | |
| 6 | 2021 | 28 | |
| 7 | 2021 | 14 | |
| 8 | 2020 | 26 | |
| 9 | 2020 | 28 | |
| 10 | 2020 | 25 | |
| 11 | 2020 | 61 | |
| 12 | 2020 | 30 | |
| 13 | 2020 | 35 | |
| 14 | 2019 | 16 | |
| 15 | 2018 | 15 | |
| 16 | 2017 | 63 | |
| 17 | 2017 | 34 | |
| 18 | 2010 | 60 | |
| 19 | Immunoconjugates comprised of drugs with impaired cellular permeability: A new approach to targeted therapy | 2004 | 2 |
| 20 | Development of potent monoclonal antibody auristatin conjugates for cancer therapybreakdown → | 2003 | 903 |
About Brian A. Mendelsohn
Brian A. Mendelsohn is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology, Immunology and Allergy, Organic Chemistry and Molecular Biology, having authored 39 papers that have together received 2.6k indexed citations. Recurring topics across this work include Monoclonal and Polyclonal Antibodies Research (29 papers), HER2/EGFR in Cancer Research (28 papers), Chemical Synthesis and Analysis (7 papers), Click Chemistry and Applications (5 papers), Cell Adhesion Molecules Research (5 papers), CAR-T cell therapy research (3 papers), Advanced Biosensing Techniques and Applications (3 papers) and Peptidase Inhibition and Analysis (3 papers). The work is most often cited by research in Radiology, Nuclear Medicine and Imaging (1.5k citations), Oncology (1.5k citations), Organic Chemistry (667 citations), Immunology and Allergy (113 citations) and Molecular Biology (1.0k citations). Brian A. Mendelsohn has collaborated with scholars based in United States, Japan and Canada. Frequent co-authors include Yutaka Matsuda, Peter D. Senter, Charles G. Cerveny, Damon L. Meyer, Brian E. Toki, Alan F. Wahl, Svetlana O. Doronina, Tim D. Bovee, Marco A. Ciufolini and Michael Torgov. Their work appears in journals such as Molecular Cancer Therapeutics, Organic Letters, Molecular Pharmaceutics, Bioconjugate Chemistry and Organic Process Research & Development.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.